Drug intelligence / Profile preview

SRO-91

Development stage: Preclinical
Lead developer: Institut Pasteur
Modality: Small Molecules

Overview

SRO-91 is a synthetic, non-natural **ribofuranosyl-1,2,3-triazole C-nucleoside** analog structurally related to ribavirin. It is designed via C-alkynyl glycosylation mediated by metallic indium and subsequent Huisgen cycloaddition. SRO-91 acts as a cytotoxic agent with **antitumor activity**, especially in ovarian and skin cancer models. It inhibits cancer cell proliferation, migration, clonogenicity, and spheroid formation, and shows a favorable therapeutic index, being more selectively toxic to tumor cells compared to normal cells. Mechanistically, SRO-91 impairs tumor cell dissemination; its activity profile is similar to ribavirin but has reduced toxicity to non-cancer cells.

Brand names: SRO-91SRO91SRO 91
Other names: ribofuranosyl-1,2,3-triazole C-nucleoside analognon-natural ribavirin analog

Beyond the preview

Go deeper on SRO-91.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRO-91.

Explore the full profile